Lexaria Bioscience (NASDAQ:LEXX) Stock Moved Up to Sell by Wall Street Zen

Wall Street Zen upgraded shares of Lexaria Bioscience (NASDAQ:LEXX) to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $22.50.

Lexaria Bioscience Price Performance

Shares of NASDAQ LEXX opened at $3.32 on Friday. The stock has a fifty day moving average price of $6.76 and a 200 day moving average price of $9.06. Lexaria Bioscience has a 1-year low of $2.77 and a 1-year high of $21.60. The company has a market cap of $7.01 million, a PE ratio of -0.65 and a beta of 0.61.

Lexaria Bioscience (NASDAQ:LEXX) last announced its quarterly earnings data on Monday, July 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Analysts anticipate that Lexaria Bioscience will post -4.05 earnings per share for the current fiscal year.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the way active pharmaceutical and nutritional compounds are absorbed and used by the body. Its principal technology, DehydraTECH, is intended to enhance the delivery, bioavailability, and performance of orally administered compounds.

The company has investigated DehydraTECH applications involving cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, antiviral compounds, and other active ingredients.